Targeting SLCs has already been successful, for example, in the treatment of type-2 diabetes by inhibiting SLC5A2 (SGLT2), a sodium-dependent glucose transporter responsible for glucose reabsorption in the kidney (Lin et al, 2015). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.